This study is testing an investigational vaccine called AV-1980R in people with preclinical Alzheimer's disease. This means you would have early signs of Alzheimer's in your body, but no memory or thinking problems. The vaccine aims to help your body create antibodies against a protein called tau, which is linked to Alzheimer's. Researchers want to see if AV-1980R is safe, how well people tolerate it, and if it creates an immune response. Up to 48 adults, aged 65-80, who are cognitively unimpaired but have specific biomarker evidence of early Alzheimer's (like a high Amyloid Probability Score 2 or APS2) can participate. Success in this study means showing the vaccine is safe and triggers an immune response. The current recruitment status is unclear.

Study design

This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled study with up to 48 participants. Participants will be assigned to receive AV-1980R at different doses or a placebo.

What's involved

Participants will receive four intramuscular injections at Weeks 0, 4, 12, and 36. Safety will be monitored through adverse events, lab tests, ECGs, MRI, and neurological assessments.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed through Week 56 after their first dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.